Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 1-10

  Brewer, George J ^a,b   Dick, Robert D ^a   Grover, Damanjit K ^a   LeClaire, Virginia ^a,b   Tseng, Michael ^a,b   Wicha, Max ^a,b   Pienta, Kenneth ^a,b   Redman, Bruce G ^a,b   Jahan, Thierry ^c   Sondak, Vernon K ^a   Strawderman, Myla ^a   LeCarpentier, Gerald ^a   Merajver, Sofia D ^a,b,d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CERULOPLASMIN; COPPER; TETRATHIOMOLYBDIC ACID;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COPPER BLOOD LEVEL; DISEASE ACTIVITY; DOSE CALCULATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MALE; METASTASIS; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; CERULOPLASMIN; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; MOLYBDENUM; NEOPLASM METASTASIS; NEOPLASMS;

EID: 0033963879     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg., 175: 409-416, 1972.
2. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
3. Folkman, J. Antiangiogenic therapy. In: De Vito, Rosenberg, and Hellman, eds., Cancer: Principles and Practice of Oncology, pp. 3075-3085. Philadelphia, PA: Lippincott-Raven Publishers, 1997.
4. Volpert, O. V., Ward, W. F., Lingen, M. W., Chesler, L., Solt, D. B., Johnson, M. D., Molteni, A., Polverini, P. J., and Bouck, N. P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Investig., 98: 671-679, 1996.
5. Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A., and Strawn, L. M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res., 56: 1615-1620, 1996.
6. Warren, R. S., Yuan, H., Malti, M. R., Gillett, N. A., and Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Investig., 95: 1789-1797, 1995.
7. Borgstom, P., Hillan, K. J., Sriramarao, P., and Ferrara, N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy for intravital videomicroscopy. Cancer Res., 56: 4032-4039, 1996.
8. Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., and Jain, R. K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA, 93: 14765-14770, 1996.
9. Borgstom, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P., and Ferrara, N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma microtumors in vivo. Prostate, 55: 1-10, 1998.
10. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
11. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Investig., 103: 159-165, 1999.
12. Merajver, S. D., Irani, J., van Golen, K., and Brewer, G. Copper depletion as an anti-angiogenic strategy in HER2-neu transgenic mice. Proc. AACR Special Conference on Angiogenesis and Cancer, B11, 1998.
13. Marshall, J. L., Wellstein, A., Rae, J., DeLap, R. J., Phipps, K., Hanfelt, J., Yunmbam, M. K., Sun, J. X., Duchin, K. L., and Hawkins, M. J. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. Clin. Cancer Res., 3: 2347-2354, 1997.
14. Iruela-Arispe, M. L., and Dvorak, H. F. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb. Haemostasis, 78: 672-677, 1997.
15. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
16. Volpert, O. V., Stellmach, V., and Bouck, N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res. Treat., 36: 119-126, 1995.
17. Salnikow, K., Wang, S., and Costa, M. Induction of activating transcription factor 1 by nickel and its role as a negative regulator of thrombospondin I gene expression. Cancer Res., 57: 5060-5066, 1997.
18. Guo, N., Krutzch, H. C., Inman, J. K., and Roberts, D. D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res., 57: 1735-1742, 1997.
19. Schapira, D. V., and Schapira, M. Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer. Breast Cancer Res. Treat., 3: 223-224, 1983.
20. Qian, X., Wang, W. N., Rothman, V., Nicosia, R. F., and Tuszynski, G. P. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 endothelial cells. Exp. Cell Res., 235: 403-412, 1997.
21. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
22. Lannutti, B. J., Gately, S. T., Quevedo, M. E., Soff, G. A., and Paller, A. S. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res., 57: 5277-5280, 1997.
23. Sim, B. K. L., O'Reilly, M. S., Liang, H., Fortier, A. H., He, W., Madsen, J. W., Lapcevich, R., and Nacy, C. A. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res., 57: 1329-1334, 1997.
24. Watanabe, T., Seno, M., Sasada, R., and Igarashi, K. Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. Mol. Endocrinol., 4: 869-879, 1990.
25. Engleka, K. A., and Maciag, T. Inactivation of human fibroblast growth factor-1 (FGF-1) activity by interaction with copper ions involves FGF-1 dimer formation induced by copper-catalyzed oxidation. J. Biol. Chem., 267: 11307-11315, 1994.
26. Shing, Y. Heparin-copper biaffinity chromatography of fibroblast growth factors. J. Biol. Chem., 263: 9059-9062, 1988.
27. Patstone, G., and Maher, P. Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptors. J. Biol. Chem., 271: 3343-3346, 1996.
28. Badet, J., Soncin, F., Guitton, J., Lamare, O., Cartwright, T., and Barritault, D. Specific binding of angiogenin to calf pulmonary artery endothelial cells. Proc. Natl. Acad. Sci. USA, 86: 8427-8431, 1989.
29. Parke, A., Bhattacherjee, P., Palmer, R. M., and Lazarus, N. R. Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am. J. Clin. Pathol., 137: 1121-1142, 1988.
30. Raju, K. S., Alesandrii, G., Zinche, M., and Gullino, P. M. Ceruloplasmin, copper ions, and angiogenesis. J. Natl. Cancer Inst., 69: 1183-1188, 1982.
31. Ziche, M., Jones, J., and Gullino, P. M. Role of prostaglandin E and copper in angiogenesis. J. Natl. Cancer Inst., 69: 475-482, 1982.
32. Brem, S. S., Zagzag, D., Tsanaclis, A. M. C., Gatley, S., Elkouby, M. P., and Brien, S. E. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am. J. Pathol., 137: 1121-1142, 1990.
33. Brem, S., Tsanaclis, A. M., and Zagzag, D. Anticopper treatment inhibits pseudopodial protrusion and invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery, 26: 391-396, 1990.
34. Brewer, G. J., Dick, R. D., Yuzbasiyan-Gurkin, V., Tankanow, R., Young, A. B., and Kluin, K. J. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch. Neurol., 48: 42-47, 1991.
35. Brewer, G. J., Dick, R. D., Johnson, V., Wang, Y., Yuzbasiyan-Gurkan, V., Kluin, K., Fink, J. K., and Aisen, A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch. Neurol., 51: 545-554, 1994.
36. Brewer, G. J., Johnson, V., Dick, R. D., Kluin, K. J., Fink, J. K., and Brunberg, J. A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol., 53: 1017-1025, 1996.
37. Brewer, G., and Merajver, S. Treatment of metastatic cancer with the anticopper, antiangiogenic drug, tetrathiomolybdate. J. Investig. Med., 47: 223A, 1999.
38. Linder, M. C., Houle, P. A., Isaacs, E., Moor, J. R., and Scott, L. E. Copper regulation of ceruloplasmin in copper-deficient rats. Enzyme (Basel), 24: 23-35, 1979.
39. Carson, P. L., Fowlkes, J. B., Roubidoux, M. A., Moskalik, A. P., Govil, A., Normolle, D., LeCarpentier, G., Nattakom, S., and Helvie, M. R. J. M. 3-D color Doppler image quantification of breast masses. Ultrasound Med. Biol., 24: 945-952, 1998.
40. LeCarpentier, G. L., Tridandapani, P. B., Fowlkes, J. B., Roubidoux, M. A., Moskalik, A. P., and Carson, P. L. Utility of 3D ultrasound in the discrimination and detection of breast cancer. RSNA EJ, in press, 1999.
41. Takahashi, K., Mulliken, J. B., Kozakewich, H. P., Rogers. R. A., Folkman, J., and Ezekowitz, R. A. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J. Clin. Investig., 93: 2357-2364, 1994.
42. Arnold, M., and Sasse, D. Quantitative and histochemical analysis of Cu, Zn, and Fe in spontaneous and induced primary tumors in rats. Cancer Res., 21: 761-766, 1961.
43. 64Cu) in tumor-bearing mice and rats. Anticancer Res., 6: 159-164, 1986.
44. Gullino, P. M., Ziche, M., and Alessandri, G. Gangliosides, copper ions and angiogenic capacity of adult tissues. Cancer Metastasis Rev., 9: 239-251, 1990.
45. Fuchs, M. G., and Sacerdote de Lustig, E. Localization of tissue copper in mouse mammary tumors. Oncology (Basel), 46: 183-187, 1989.
46. Culotta, V. C., Klomp, L. W. J., Strain, J., Casareno, R. L. B., Krems, B., and Gitlin, J. D. The copper chaperone for superoxide dismutase. J. Biol. Chem., 272: 23469-23472, 1997.